Literature DB >> 18298802

E3 ubiquitin ligase E6AP-mediated TSC2 turnover in the presence and absence of HPV16 E6.

Li Zheng1, Huirong Ding, Zheming Lu, Yong Li, Yaqi Pan, Tao Ning, Yang Ke.   

Abstract

We previously found that HPV16 E6 causes the degradation of the tumor suppressor protein TSC2, resulting in the phosphorylation of S6 kinase and S6 even in the absence of insulin. In the present study, we investigated the role of E6-associated protein (E6AP) in HPV16 E6-induced TSC2 degradation. Our results demonstrated that TSC2 was targeted for degradation in the presence or absence of HPV16 E6. Over-expression of E6AP enhanced the degradation of TSC2 by HPV16 E6, while expression of a dominant negative E6AP (C833A) inhibited the E6-induced degradation. Additionally, by using shRNAs to block E6AP expression in HPV16 positive and negative cells, we found a significantly prolonged TSC2 half-life. An in vivo ubiquitination assay was done to reveal that E6AP promoted the ubiquitination of TSC2 independent of HPV16 E6. We further found that TSC2 bound E6AP in the presence as well as in the absence of HPV16 E6. The binding regions on E6AP and TSC2 have been identified as amino acid (aa) 260-316, aa 428-500 and aa 1-175, aa 1251-1807, respectively. Taken together, degradation of TSC2 is mediated by E6AP ubiquitin ligase.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18298802     DOI: 10.1111/j.1365-2443.2008.01162.x

Source DB:  PubMed          Journal:  Genes Cells        ISSN: 1356-9597            Impact factor:   1.891


  33 in total

Review 1.  Cellular transformation by human papillomaviruses: lessons learned by comparing high- and low-risk viruses.

Authors:  Aloysius J Klingelhutz; Ann Roman
Journal:  Virology       Date:  2012-01-27       Impact factor: 3.616

2.  Metformin impairs the growth of liver kinase B1-intact cervical cancer cells.

Authors:  Xuxian Xiao; Qiongqiong He; Changming Lu; Kaitlin D Werle; Rui-Xun Zhao; Jianfeng Chen; Ben C Davis; Rutao Cui; Jiyong Liang; Zhi-Xiang Xu
Journal:  Gynecol Oncol       Date:  2012-06-24       Impact factor: 5.482

3.  Identification and proteomic analysis of distinct UBE3A/E6AP protein complexes.

Authors:  Gustavo Martínez-Noël; Jeffrey T Galligan; Mathew E Sowa; Verena Arndt; Thomas M Overton; J Wade Harper; Peter M Howley
Journal:  Mol Cell Biol       Date:  2012-05-29       Impact factor: 4.272

Review 4.  Papillomavirus E6 oncoproteins.

Authors:  Scott B Vande Pol; Aloysius J Klingelhutz
Journal:  Virology       Date:  2013-05-24       Impact factor: 3.616

Review 5.  Tinkering with translation: protein synthesis in virus-infected cells.

Authors:  Derek Walsh; Michael B Mathews; Ian Mohr
Journal:  Cold Spring Harb Perspect Biol       Date:  2013-01-01       Impact factor: 10.005

6.  Imbalanced mechanistic target of rapamycin C1 and C2 activity in the cerebellum of Angelman syndrome mice impairs motor function.

Authors:  Jiandong Sun; Yan Liu; Stephanie Moreno; Michel Baudry; Xiaoning Bi
Journal:  J Neurosci       Date:  2015-03-18       Impact factor: 6.167

7.  Genome-wide gene expression profiling of the Angelman syndrome mice with Ube3a mutation.

Authors:  Daren Low; Ken-Shiung Chen
Journal:  Eur J Hum Genet       Date:  2010-06-23       Impact factor: 4.246

8.  Proteotranscriptomic Measurements of E6-Associated Protein (E6AP) Targets in DU145 Prostate Cancer Cells.

Authors:  Twishi Gulati; Cheng Huang; Franco Caramia; Dinesh Raghu; Piotr J Paul; Robert J A Goode; Simon P Keam; Scott G Williams; Sue Haupt; Oded Kleifeld; Ralf B Schittenhelm; Cristina Gamell; Ygal Haupt
Journal:  Mol Cell Proteomics       Date:  2018-02-20       Impact factor: 5.911

9.  The Angelman syndrome protein Ube3a/E6AP is required for Golgi acidification and surface protein sialylation.

Authors:  Kathryn H Condon; Jianghai Ho; Camenzind G Robinson; Cyril Hanus; Michael D Ehlers
Journal:  J Neurosci       Date:  2013-02-27       Impact factor: 6.167

Review 10.  Papillomavirus E6 proteins.

Authors:  Heather L Howie; Rachel A Katzenellenbogen; Denise A Galloway
Journal:  Virology       Date:  2008-12-10       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.